Trial Profile
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIOPKD
- 22 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Aug 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2019.
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.